TREATMENT GOALS FROM THE PERSPECTIVE OF IMMUNOGLOBULIN A NEPHROPATHY PATIENTS - RESULTS FROM A REAL-WORLD STUDY

Back

E-Poster

https://storage.unitedwebnetwork.com/files/1099/acd029a8686c5d0f0a9d888f5a781c16.pdf

Abstract Title

First Name *

Aneesh

Last Name *

Thomas George

Co-author 1

Richard Lafayette czar@stanford.edu Stanford University Medical Center Nephrology Stanford

Co-author 2

Sydney Tang scwtang@hku.hk The University of Hong Kong Nephrology Hong Kong SAR

Co-author 3

Serge Smeets serge.smeets@novartis.com Novartis Pharma AG Medical Basel

Co-author 4

Carolina Aldworth carolina.aldworth@novartis.com Novartis Pharmaceuticals Corporation Medical East Hanover

Co-author 5

Raymond Przybysz raymond.przybysz@novartis.com Novartis Pharmaceuticals Corporation RWE and Innovative Evidence East Hanover

Co-author 6

Emma Chatterton emma.chatterton@adelphigroup.com Adelphi Real World Rare Diseases Bollington

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15